By combining in vitro functional assays with single-cell and spatial transcriptomics analyses, we specifically sought to determine how IRF4 expression influences B cell dynamics within the TME, contributes to TLS heterogeneity, and ultimately impacts ccRCC progression, thereby identifying potential mechanisms driving immune evasion and revealing novel therapeutic vulnerabilities. The gene discussed is IRF4; the disease is nonpapillary renal cell carcinoma.